• Standard BioTools Inc LAB.OQ reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended December 31, identical to the same quarter last year. The mean expectation of three analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -9 cents to -5 cents per share.

• Revenue fell 56.5% to $23.80 million from a year ago; analysts expected $18.50 million.

• Standard BioTools Inc's reported EPS for the quarter was 5 cents​.

• The company reported a quarterly loss of $34.69 million.

• Standard BioTools Inc shares had fallen by 13.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Standard BioTools Inc is $1.55, about 25.8% above its last closing price of $1.15

This summary was machine generated from LSEG data February 25 at 12:19 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)